Selena Lorrey
YOU?
Author Swipe
View article: Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity
Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity Open
Purpose: Exhaustion represents a collection of programmed T cell differentiation states and an important mode of T cell dysfunction. T cell progression from progenitor to terminal exhaustion is associated with upregulation of the transcrip…
View article: IMMU-81. Glioblastoma and other intracranial pathologies elicit systemic sympathetic hyperactivity that limits immunotherapeutic responses
IMMU-81. Glioblastoma and other intracranial pathologies elicit systemic sympathetic hyperactivity that limits immunotherapeutic responses Open
Immunotherapies remain largely ineffective against intracranial malignancies such as glioblastoma (GBM), in part due to profound systemic and local immune dysfunction. Hallmarks of systemic immune dysfunction include bone marrow T cell seq…
View article: IMMU-52. Novel Insights into T cell Exhaustion in GBM and other Solid Tumors
IMMU-52. Novel Insights into T cell Exhaustion in GBM and other Solid Tumors Open
While terminally exhausted T cells (Tex_term) retain important anti-tumor cytotoxic functions, it is the relative renewal of the stem-like progenitor exhaustion state (Tex_prog) that better reflects immunotherapeutic responsivity. The cell…
View article: Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion
Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion Open
Whereas terminally exhausted T (Tex_term) cells retain anti-tumor cytotoxic functions, the frequencies of stem-like progenitor-exhausted T (Tex_prog) cells better reflect immunotherapeutic responsivity. Here, we examined the intratumoral c…
View article: IMMU-09. REVERSING SYSTEMIC T CELL DYSFUNCTION TO LICENSE IMMUNOTHERAPY IN INTRACRANIAL TUMORS
IMMU-09. REVERSING SYSTEMIC T CELL DYSFUNCTION TO LICENSE IMMUNOTHERAPY IN INTRACRANIAL TUMORS Open
Intracranial tumors present unique challenges for immunotherapy. These can include both local and systemic modes of immune suppression, the mechanistic underpinnings of which are incompletely understood. Our work reveals that intracranial …
View article: IMMU-05. TNFR2 IS A NOVEL MARKER OF EXHAUSTION AND TNFR2 BLOCKADE IMPROVES SUBCUTANEOUS TUMOR CONTROL
IMMU-05. TNFR2 IS A NOVEL MARKER OF EXHAUSTION AND TNFR2 BLOCKADE IMPROVES SUBCUTANEOUS TUMOR CONTROL Open
Checkpoint inhibitors have been successful in various tumors. However, these treatments have failed in glioblastoma. Approaches harnessing the immune response are hindered by multiple factors, including T cell exhaustion. TOX is particular…
View article: IMMU-52. A NOVEL MHC-INDEPENDENT MECHANISM FOR CD8+ T CELL KILLING
IMMU-52. A NOVEL MHC-INDEPENDENT MECHANISM FOR CD8+ T CELL KILLING Open
The long-accepted paradigm for both cellular and antitumor immunity relies upon tumor cell kill by CD8+ T cells recognizing cognate antigens presented in the context of target cell major histocompatibility complex class I (MHC I) molecules…
View article: IMMU-53. ANTIGEN PRESENTATION BY TUMOR-ASSOCIATED MACROPHAGES MEDIATES PROGENITOR TO TERMINAL EXHAUSTION TRANSITION IN GBM AND OTHER SOLID TUMORS
IMMU-53. ANTIGEN PRESENTATION BY TUMOR-ASSOCIATED MACROPHAGES MEDIATES PROGENITOR TO TERMINAL EXHAUSTION TRANSITION IN GBM AND OTHER SOLID TUMORS Open
While terminally exhausted T cells (Tex_term) retain important anti-tumor cytotoxic function, it is the relative preservation of renewable, stem-like progenitor exhaustion (Tex_prog) that better indicates immunotherapeutic responsivity. Al…
View article: Glioblastoma and other intracranial tumors elicit systemic sympathetic hyperactivity that limits immunotherapeutic responses
Glioblastoma and other intracranial tumors elicit systemic sympathetic hyperactivity that limits immunotherapeutic responses Open
Intracranial tumors present unique challenges for immunotherapy. These can include both local and systemic modes of immune suppression whose mechanistic underpinnings are incompletely understood. Here, we reveal that tumors harbored intrac…
View article: IMMU-49. BETA-ADRENERGIC BLOCKADE LICENSES THE USE OF IMMUNOTHERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS
IMMU-49. BETA-ADRENERGIC BLOCKADE LICENSES THE USE OF IMMUNOTHERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS Open
Immunotherapy is less effective against intracranial metastases compared to extracranial metastases and ineffective against primary brain tumors such as glioblastoma. Brain tumors present a unique challenge to in the context of immunothera…
View article: 891 Beta-adrenergic blockade licenses the use of immunotherapy in primary and metastatic brain tumors
891 Beta-adrenergic blockade licenses the use of immunotherapy in primary and metastatic brain tumors Open
Background Immunotherapy is less effective against intracranial metastases compared to extracranial metastases and ineffective against primary brain tumors such as glioblastoma. Brain tumors present a unique challenge to in the context of …
View article: Antigen presentation by tumor-associated macrophages drives tumor-infiltrating T cells from a progenitor exhaustion state to terminal exhaustion
Antigen presentation by tumor-associated macrophages drives tumor-infiltrating T cells from a progenitor exhaustion state to terminal exhaustion Open
SUMMARY Whereas terminally exhausted T (Tex_term) cells retain anti-tumor cytotoxic functions, the frequencies of stem-like progenitor exhausted T (Tex_prog) cells better reflect immunotherapeutic responsivity. Here, we examined the intrat…
View article: CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis
CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis Open
The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell killing by CD8 + T cells recognizing cognate antigens presented in the context of target cell major histocompatibility complex (MHC) class I (MHC-I) mol…
View article: BSBM-19 CROSS-PRESENTATION BY TUMOR-ASSOCIATED MACROPHAGES MEDIATES THE TRANSITION FROM PROGENITOR TO TERMINAL T CELL EXHAUSTION IN PRIMARY AND METASTATIC BRAIN TUMORS
BSBM-19 CROSS-PRESENTATION BY TUMOR-ASSOCIATED MACROPHAGES MEDIATES THE TRANSITION FROM PROGENITOR TO TERMINAL T CELL EXHAUSTION IN PRIMARY AND METASTATIC BRAIN TUMORS Open
Glioblastoma (GBM) and brain metastases remain largely resistant to immunotherapeutic intervention. T cell exhaustion, a differentiation state characterized by loss of function and persistence, contributes to this resistance. Two exhaustio…
View article: SYST-05 BETA-ADRENERGIC BLOCKADE LICENSES THE USE OF IMMUNOTHERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS
SYST-05 BETA-ADRENERGIC BLOCKADE LICENSES THE USE OF IMMUNOTHERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS Open
Brain tumors present a unique challenge to in the context of immunotherapy, as these patients are immunosuppressed not just at the tumor but also outside the CNS. The systemic immunosuppression observed in brain tumor patients limits the c…
View article: Data from Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
Data from Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19 Open
Purpose:T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR …
View article: Data from Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
Data from Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19 Open
Purpose:T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR …
View article: Supplementary Data from Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
Supplementary Data from Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19 Open
Supplementary Materials and Data
View article: Supplementary Data from Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
Supplementary Data from Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19 Open
Supplementary Materials and Data
View article: A Novel MHC-Independent Mechanism of Tumor Cell Killing by CD8<sup>+</sup>T Cells
A Novel MHC-Independent Mechanism of Tumor Cell Killing by CD8<sup>+</sup>T Cells Open
The accepted paradigm for both cellular and antitumor immunity relies upon tumor cell kill by CD8 + T cells recognizing cognate antigens presented in the context of target cell major histocompatibility complex class I (MHC I) molecules. Li…
View article: Systemic immune derangements are shared across various CNS pathologies and reflect novel mechanisms of immune privilege
Systemic immune derangements are shared across various CNS pathologies and reflect novel mechanisms of immune privilege Open
Background The nervous and immune systems interact in a reciprocal manner, both under physiologic and pathologic conditions. Literature spanning various CNS pathologies including brain tumors, stroke, traumatic brain injury and de-myelinat…
View article: CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?
CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer? Open
In chronic infections and in cancer, persistent antigen stimulation under suboptimal conditions can lead to the induction of T-cell exhaustion. Exhausted T cells are characterized by an increased expression of inhibitory markers and a prog…
View article: Correction: Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.
Correction: Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. Open
VOLUME 295 (2020) PAGES 3431–3446 In response to a reviewer's request to change the x axis units of our dose-response curves from µm to m, we mistakenly changed the numbers to mm while labeling as m. The numbers in the original submission …
View article: Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease
Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease Open
Purpose: Although pituitary adenoma is classified as benign, Cushing disease is associated with significant morbidity due to the numerous sequelae of elevated cortisol levels. Successful therapy for Cushing disease remains elusive due to h…
View article: Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19 Open
Our findings demonstrate that CAR T cells targeting CD79b alone or in combination have promise for treating and preventing CD19 antigen escape in B-cell lymphomas.